Company Legal Name
Latest Valuation
Founded Year
Headquarter
Neuspera Medical develops implantable neuromodulation devices designed to treat urinary urge incontinence through advanced wireless charging technology. Based in San Jose, the company addresses a significant medical need affecting millions of patients worldwide who suffer from overactive bladder conditions. Neuspera's innovative approach combines targeted neural stimulation with convenient wireless power delivery, potentially offering patients a more user-friendly alternative to existing treatment options. The company's technology represents a notable advancement in the urological device market, where traditional solutions often require invasive battery replacement procedures. Neuspera continues to focus on advancing its neuromodulation platform for broader therapeutic applications.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
